Scholarlink

<p>More than 400,000 women worldwide are diagnosed with endometrial carcinoma (EC) each year, with a&#xa0;steadily increasing incidence. Despite numerous advances in treatment, including the use of immune checkpoint inhibitors, endocrine therapy continues to play a&#xa0;relevant role. Following careful patient selection, it represents a&#xa0;meaningful and generally well-tolerated treatment option both for patients with limited fitness for intensive therapy and for young women seeking fertility preservation. Progestins have been used for this purpose for many years. Current research focuses on the role of local progestin administration in fertility-sparing treatment strategies, as well as on the use of aromatase inhibitors in combination with Cyclin-dependent kinase 4/6 (CDK4/6)&#xa0;inhibitors with the aim of improving response rates in recurrent EC. In addition, the potential benefit of additive therapeutic approaches, such as metformin, is being investigated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Möglichkeiten der endokrinen Therapie des Endometriumkarzinoms

  • 期刊论文

  • 发表日期：

    2026年3月22日

查看全文
  • Magdalena Steber,
  • Anna Albert,
  • Joachim Diessner

摘要

More than 400,000 women worldwide are diagnosed with endometrial carcinoma (EC) each year, with a steadily increasing incidence. Despite numerous advances in treatment, including the use of immune checkpoint inhibitors, endocrine therapy continues to play a relevant role. Following careful patient selection, it represents a meaningful and generally well-tolerated treatment option both for patients with limited fitness for intensive therapy and for young women seeking fertility preservation. Progestins have been used for this purpose for many years. Current research focuses on the role of local progestin administration in fertility-sparing treatment strategies, as well as on the use of aromatase inhibitors in combination with Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with the aim of improving response rates in recurrent EC. In addition, the potential benefit of additive therapeutic approaches, such as metformin, is being investigated.